跳至主要内容
临床试验/ISRCTN43482138
ISRCTN43482138已完成3 期

A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancer

The University of Liverpool (UK)0 个研究点目标入组 1,062 人开始时间: 2005年12月14日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
1,062

研究概览

简要总结

2014 Results article in http://www.ncbi.nlm.nih.gov/pubmed/24954781 results

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Aged over 18 years
  • 2. Histologically or cytologically proven pancreatic ductal adenocarcinoma carcinoma
  • 3. Locally advanced or metastatic disease precluding curative surgical resection
  • 4. Contrast enhanced Computed Tomography (CT) scan of the thorax, abdomen and pelvis within 28 days of randomisation
  • 5. Unidimensionally measurable disease (CT) in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines
  • 6. World Health Organisation (WHO) performance status zero, one or two
  • 7. Platelets more than 100 x 10^9/l; white blood cell count (WBC) more than 3 x 10^9/l; neutrophils more than 1.5 x 10^9/l at entry
  • 8. Serum bilirubin less than 35 µmol/l
  • 9. Calculated creatinine clearance over 50 ml/min
  • 10. No concurrent uncontrolled medical condition
  • 11. No previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix
  • 12. Life expectancy more than three months
  • 13. Adequate contraceptive precautions if relevant
  • 14. Informed written consent

排除标准

  • 1. Medical or psychiatric conditions compromising informed consent
  • 2. Intracerebral metastases or meningeal carcinomatosis
  • 3. Clinically significant serious disease or organ system disease not currently controlled on present therapy
  • 4. Uncontrolled angina pectoris
  • 5. Pregnancy or breast feeding
  • 6. Treatment with chemotherapy, radiotherapy or other investigational drug within the last four weeks prior to inclusion
  • 7. Known malabsorption syndromes
  • 8. Patients with a known hypersensitivity to Fluorouracil (5-FU) or with a Dihydropyrimidine Dehydrogenase (DPD) deficiency
  • 9. Immunosuppressive therapy less than four weeks prior to the start of treatment
  • 10. People of child-bearing potential unless effective methods of contraception are used

研究者

发起方
The University of Liverpool (UK)

相似试验